Synthesis of the title oligosaccharides was performed with the use of peracetylated L-glycero-beta-D-manno-heptosyl trichloroacetimidate as the heptosyl donor and (oligo)glucosyl accepters bearing acyl and acetal protecting groups.
Large-Scale Synthesis of Crystalline 1,2,3,4,6,7-Hexa-<i>O</i>-acetyl-<scp>L</scp>-<i>glycero-</i>α-<scp>D</scp>-<i>manno</i>-heptopyranose
作者:Christian Stanetty、Ian R. Baxendale
DOI:10.1002/ejoc.201500024
日期:2015.4
The higher-carbon sugar l-glycero-d-manno-heptose is a major constituent of the inner core region of the lipopolysaccharide (LPS) of many Gram-negative bacteria. All preparative routes used to date require multiple steps, and scalability has been rarely addressed. Here a highly practical synthesis of crystalline 1,2,3,4,6,7-hexa-O-acetyl-l-glycero-alpha-d-manno-heptopyranose by a simple four-step sequence
A Bioactive Synthetic Outer‐Core Oligosaccharide Derived from a
<i>Klebsiella pneumonia</i>
Lipopolysaccharide for Bacteria Recognition
作者:Dushen Chen、Akhilesh K. Srivastava、Justyna Dubrochowska、Lin Liu、Tiehai Li、Joseph P. Hoffmann、Jay K. Kolls、Geert‐Jan Boons
DOI:10.1002/chem.202203408
日期:——
A chemical synthesised outercore tetra- and pentasaccharide derivedfrom the lipopolysaccharide of K. pneumoniae conjugated to the carrier proteins CRM197 and BSA elicited in mice antibodies that recognized isolated LPS as well as various strains of K. pneumoniae demonstrating they can induce relevant antigenic responses.
Pathogen-specific cargo delivery and diagnostic platform based on mesoporous silica nanoparticles
申请人:The Regents of the University of California
公开号:US11045555B2
公开(公告)日:2021-06-29
In various embodiments nanoparticle drug delivery vehicles are provided that specifically deliver a cargo to a target pathogenic organism. In certain embodiments the drug delivery vehicle comprises a mesoporous silica nanoparticle comprising a plurality of pores and an outer surface through which the pores are disposed; a cargo disposed in the pores; one or more antigens attached to the surface of the nanoparticle; an antibody that specifically binds the antigens and are bound to the antigens, wherein the antibody inhibits diffusion of the cargo out of the pores and permit release of the cargo when the drug delivery vehicle is in the presence of the antigen or a pathogen displaying the antigen.